Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
84.18
-1.02 (-1.20%)
At close: Apr 28, 2026, 4:00 PM EDT
83.58
-0.60 (-0.71%)
After-hours: Apr 28, 2026, 6:17 PM EDT
Rhythm Pharmaceuticals Employees
Rhythm Pharmaceuticals had 414 employees as of December 31, 2025. The number of employees increased by 131 or 46.29% compared to the previous year.
Employees
414
Change (1Y)
131
Growth (1Y)
46.29%
Revenue / Employee
$458,350
Profits / Employee
-$487,722
Market Cap
5.75B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| PTC Therapeutics | 991 |
| Mirum Pharmaceuticals | 372 |
| Immunovant | 362 |
| Cogent Biosciences | 258 |
| Celcuity | 155 |
| CG Oncology | 142 |
| Centessa Pharmaceuticals | 118 |
RYTM News
- 12 days ago - Rhythm Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference - Transcripts
- 19 days ago - Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026 - GlobeNewsWire
- 25 days ago - Rhythm Pharmaceuticals Announces Changes to Board of Directors - GlobeNewsWire
- 4 weeks ago - Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment - GlobeNewsWire
- 5 weeks ago - PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide) - PRNewsWire
- 5 weeks ago - Rhythm Pharmaceuticals Transcript: Study update - Transcripts
- 5 weeks ago - Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity - GlobeNewsWire
- 6 weeks ago - Rhythm Pharmaceuticals Transcript: Study result - Transcripts